Claire Keast-Butler

Cooley advised Bicycle Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of medicines referred to as Bicycle molecules, on its $555.5 million private placement offering. Partners Laura Berezin, Jaime Chase and Claire Keast-Butler led the Cooley team.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.

Cooley advised Silence Therapeutics in a $56.5 million registered direct offering of 5,950,000 American Depositary Shares (ADS), each representing three ordinary shares, at a price of $9.50 per ADS. Silence is a biotechnology company focused on discovering and developing molecules incorporating novel short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Partners Josh Kaufman, Div Gupta, Nicolas H.R. Dumont and Claire Keast-Butler led the Cooley team.

Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.